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Abstract. The present study was carried out to examine the role of endogenous dopamine and somatostatin in the mechanisms involved in the restricted feeding-induced inhibition of TSH secretion in rats. GH secretion was examined in parallel. Restricted feeding by 50% or 75% was associated with a decrease in the pituitary and circulating levels of TSH and GH in both untreated and TRH\x=req-\ treated groups (p<0.001), the changes being proportional to the feeding level. Intravenous injections of the dopamine antagonists, domperidone or haloperidol, failed to affect the magnitude of the differences in plasma TSH and GH levels among control and food-restricted groups, indicating that dopaminergic mechanisms had little effect on the regulation of TSH and GH secretion during restricted feeding in rats. Cerebroventricular injection of somatostatin anti-serum resulted in a marked increase in plasma TSH and GH levels in all the experimental groups (p<0.001). The increase in plasma GH and TSH induced by somatostatin anti-serum was greater in rats fed a 25% diet than in either controls or rats fed 50% of the diet; the values for the latter two groups were also different (p<0.001). The Results are given as means ± sd. Analysis of variance followed by Tukey's multiple range test were used to analyse the data. Differences betwen groups were consid¬ ered to be significant at p<0.05.
Results
The data in Fig. 1 As previously reported (6, 11) , food restriction decreased basal TSH levels as well as TSH released in response to TRH administration (Fig. 2) (Fig. 3) Fig. 4 , the mean plasma GH levels within an experimental group were indistinguish¬ able when comparing the values in vehicle-, normal rabbit serum-, domperidone-, TRH-, and dompe¬ ridone-plus TRH-treated animals. Within each treatment, plasma GH levels in control rats were 1.8-fold and 3.5-fold higher than those in Group 1 and 2, respectively. In contrast, SRIH anti-serum increased plasma GH differently from all other treatments (p<0.001) within each group. SRIH anti-serum induced a 7-fold increase in plasma GH in Group 1 rats and a 12-fold one in Group 2 rats, which were significantly (p<0.001) higher than the 5-fold elevation observed in control rats. However, after SRIH anti-serum injection plasma GH con¬ centrations were higher in control rats than in food-restricted animals.
Discussion
In the present study we provide evidence already available (6, 11, 12) 
